Not available
Quote | ProQR Therapeutics N.V. (NASDAQ:PRQR)
Last: | $2.29 |
---|---|
Change Percent: | -3.78% |
Open: | $2.41 |
Close: | $2.38 |
High: | $2.47 |
Low: | $2.2375 |
Volume: | 81,363 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | ProQR Therapeutics N.V. (NASDAQ:PRQR)
2024-03-13 07:10:53 ET More on ProQR Seeking Alpha’s Quant Rating on ProQR Historical earnings data for ProQR Financial information for ProQR Read the full article on Seeking Alpha For further details see: ProQR reports FY results
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinic Accelerated development of Axiomer™ for CNS applications via...
Message Board Posts | ProQR Therapeutics N.V. (NASDAQ:PRQR)
Subject | By | Source | When |
---|---|---|---|
Nice rebound! | KeepOn | investorshub | 04/15/2023 2:27:13 AM |
$0.4~ | Alan Brown | investorshub | 01/09/2023 12:10:35 AM |
Ya.... | Alan Brown | investorshub | 01/07/2023 4:48:06 AM |
znewcar1: $PRQR 63% v88,4M c2.70 f71,43M H3.1 ML1.13 LL.53 | znewcar1 | investorshangout | 12/22/2022 9:11:25 PM |
Eli Lilly sends ProQR 35% higher after expanding | subslover | investorshub | 12/22/2022 6:26:10 PM |
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinic Accelerated development of Axiomer™ for CNS applications via...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against an opposition filed in Japan against a pat...
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and mice Functional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic a...